ArticleJACC. Case reports2026
Permissive Cardiotoxicity in HER2-Positive Metastatic Breast Cancer With Moderate Left Ventricular Dysfunction.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPermissive cardiotoxicity is increasingly recognized as important in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, where oncologic benefits may outweigh cardiac risks. CASE SUMMARY: A 49-year-old woman with HER2-positive, breast cancer gene 2-mutated metastatic breast cancer developed moderate left ventricular systolic dysfunction (ejection fraction 38%, global longitudinal strain -13.4%) and moderate-to-severe mitral regurgitation 4 months after initiating trastuzumab and pertuzumab. HER2 therapy was temporarily held, and guideline-directed medical therapy (GDMT) was initiated. After partial cardiac recovery, HER2-blockade was resumed under close surveillance. Her left ventricular ejection fraction improved to 52% (global longitudinal strain -17.5%) with GDMT despite continued HER2 therapy. DISCUSSION: The decision to resume HER2 therapy was based on multidisciplinary consensus, incorporating partial cardiac recovery, absence of clinical congestive heart failure, and metastatic disease burden. GDMT enabled the safe resumption of HER2-blockade despite LVEF <40%. TAKE-HOME MESSAGES: Optimal GDMT supports cardiac recovery in patients with asymptomatic left ventricular dysfunction, allowing for continued HER2 therapy. Integrated cardio-oncology care is essential to balance cancer control with cardiovascular safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.